Table 1.
LV morphology and function in ADR-treated mice
| n | HR, beats/min | EDV, μl | ESV, μl | SV, μl | EF, % | CO, ml/min | LV Mass, mg | PFR, μl/ms | |
|---|---|---|---|---|---|---|---|---|---|
| Control | 13 | 519 ± 26 | 49.7 ± 8.7 | 16.3 ± 3.5 | 33.4 ± 5.9 | 67.3 ± 3.9 | 17.4 ± 3.4 | 94.1 ± 16.4 | 0.56 ± 0.13 |
| ADR (6 wk) | 5 | 519 ± 29 | 45.5 ± 3.5 | 16.1 ± 3.5 | 29.4 ± 3.2 | 64.7 ± 6.1 | 15.3 ± 2.6 | 79.1 ± 12.3 | 0.51 ± 0.06 |
| ADR (8 wk) | 5 | 508 ± 80 | 55.8 ± 11.2 | 24.4 ± 4.4 | 31.4 ± 7.6 | 55.9 ± 4.2*† | 15.5 ± 2.4 | 78.0 ± 8.4 | 0.34 ± 0.12* |
| ADR (10 wk) | 5 | 525 ± 46 | 48.8 ± 9.8 | 23.0 ± 6.3 | 25.8 ± 4.7 | 53.2 ± 4.7*† | 13.4 ± 1.9* | 73.8 ± 10.0* | 0.27 ± 0.08*† |
Values are means ± SD; n, number of mice. HR, heart rate; EDV, end-diastolic volume; ESV, end-systolic volume; SV, systolic volume; EF, ejection fraction; CO, cardiac output, LV, left ventricular; PFR, peak filling rate.
*
P ≤ 0.05 compared with control;
†
P ≤ 0.05 compared to 6 wk after 1st Adriamycin (ADR) injection.